ERCC1在非小细胞肺癌中的表达及与临床预后的相关性

doi:10.11904/j.issn.1002-3070.2014.06.009

Abstract

Abstract:

Objective To explore the expression of Excision repair cross-completion 1 in non-small cell lung cancer and to analyze its clinical significance.Methods ERCC1 protein expression was detected by IHC method in 160 cases of non-small cell lung cancer tissue.We analyzed relationship between the ERCC1 expression and clinicopathological parameters of non-small cell lung cancer,as well as its correlation between ERCC1 expression and the prognosis.At the same time,160 cases of intraoperative specimens were primarily cultured.The relationship between ERCC1 expression and the drug sensitivity of DDP was analyzed.Results ERCC1 protein was mainly expressed in the nucleus.ERCC1 protein expression in lung cancer tissue showed no relationship with age,gender,tumor size and pathological types.ERCC1 protein expression was associated with TNM stages and lymph node metastases.High expression of ERCC1was significantly correlated with poor prognosis in patients,indicating that ERCC1 is the independent factor of NSCLC patients.MTT results showed that the positive expression rate of ERCC1 in DDP sensitive groups was higher than in DDP resistant groups.Conclusion ERCC1 is an independent factor influencing the prognosis of non-small cell lung cancer,and associated with DDP resistance.

Key words: ERCC1, Non-small cell lung cancer, Prognosis

CLC Number:

R734.2

ZHOU Daming,LU Qingfeng,CHEN Guangyu. ERCC1 expression and prognosis in non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 524-529.

References

1 陈万青,郑荣寿,张思维,等.2003-2007年中国肺癌发病与死亡分析[J].实用肿瘤学杂志,2012,26(1):6-10.
2 Crinò L,Weder W,Van Meerbeeck J,et al.Early stage and locally advanced(non-metastatic)non-small-cell lung cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(Suppl 5):v103-v115.
3 Reed E.Platinum-DNA adduct,nucleotide excision repair and platinum based anti-cancer chemotherapy[J].Cancer Treat Rev,1998,24(5):331-344.
4 De Dosso S,Zanellato E,Nucifora M,et al.ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy[J].Cancer Chemother Pharmacol,2013,72(1):159-165.
5 Park KW,Jung ES,Kim DG,et al.ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer,but not in intrahepatic cholangiocarcinoma[J].Cancer Res Treat,2013,45(1):63-69.
6 Yuanming L,Lineng Z,Baorong S,et al.BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer[J].BMC Cancer,2013,13(5):103-107.
7 Yan D,Wei P,An G,et al.Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer[J].J Cardiothorac Surg,2013,8(6):149-151.
8 Tiseo M,Bordi P,Bortesi B,et al.ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J].Br J Cancer,2013,108(8):1695-1703.
9 冷雪峰,冼磊,陈铭伍,等.非小细胞肺癌组织中ERCC1及TUBB3基因mRNA的表达及其临床意义[J].肿瘤预防与治疗,2012,25(1):1-5.
10 王巍炜,李高峰,巫正伟,等.ERCC1表达在Ⅲ期非小细胞肺癌含铂方案新辅助化疗中的意义[J].山东医药,2009,49(52):3-5.
11 Sodja E,Knez L,Kern I,et al.Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy[J].Eur J Cancer,2012,48(18):3378-3385.
12 Han Y,Wang XB,Xiao N,et al.mRNA expression and clinical significance of ERCC1,BRCA1,RRM1,TYMS and TUBB3 in postoperative patients with non-small cell lung cancer[J].Asian Pac J Cancer Prev,2013,14(5):2987-2990.
13 杨春雨,刘炜,蔡莉.人非小细胞肺癌体外抗肿瘤药物敏感性的实验研究[J].实用肿瘤学杂志,2011,25(5):457-460.
14 Ugurel S,Schadendorf D,Pfohler C,et al.In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma:a multicenter phase II trial of the Dermatologic Cooperative Oncology Group[J].Clin Cancer Res,2006,12(18):5454-5463.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[3]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[4]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[5]	LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.
[6]	ZHAO Fengjuan, WANG Qi, REN Yunhong, WEI Jueling, LI Lequn, ZHAO Xinhua, TANG Juan, YOU Xuemei. Changes of serum CRP and hs-CRP levels in patients with liver cancer and depression and their influence on prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 27-33.
[7]	ZHANG Fengchun, JIANG Ying, LIU Zhaonan, YAN Ningning, CUI Hongquan, XU Yingchun. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 34-39.
[8]	MA Jianli, ZHANG Minghui, JI Hongfei, XU Xiangying. Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 40-46.
[9]	YANG Hongbo, SHI Jie, YE Yong, LI Wencheng, DENG Zhaoping. Expression of COL5A2 in bladder cancer tissues and its correlation with clinicopathological features and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 52-56.
[10]	WANG Yalong, LYU Zhangyan, ZHANG Fan, FENG Xiaoshuang, WEI Luopei, LI Xin, WEN Yan, GAO Yushun, XUE Qi, GAO Shugeng, TAN Fengwei. Relationship between human papillomavirus infection and prognosis of lung cancer:A meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 520-526.
[11]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[12]	XIAO Hongwei, CHEN Sheng, WANG Yanliang, SU Xueliang. The prognostic and influence factors analysis of transanal local resection for stage T₁ rectal cancer with the distance from anal margin ≤8 cm [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 545-549.
[13]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[14]	WANG Yiran, HUANG Wei, YIN Lei, LIU Lin, ZHOU Xiaoping, NIU Xingjian, YANG Yue, AN Weiwei, JI Hongfei. The ratio of neutrophil to lymphocyte in the efficacy and prognosis of concurrent chemoradiotherapy in patients with cervical cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 404-409.
[15]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.

ERCC1 expression and prognosis in non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments